After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars …
When some Moderna COVID-19 vaccine vials were found to be contaminated with metallic shards last year in Japan, the company suffered a reputation crisis in …
Moderna has new data backing the use of its COVID-19 vaccine Spikevax at a low dose in the youngest children under the age of 6, …
Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come. Germany will pay …
It’s finally here: After a series of delays in the lead-up to Novavax’s COVID-19 vaccine filing with the FDA, the biotech has completed its emergency …
The neuronal protein alpha-synuclein has long been a target for Parkinson’s disease research, but it has delivered mixed results across multiple different therapeutics. Now, a …
With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. …
Developing a COVID-19 vaccine at breakneck speed was a monumental achievement for Pfizer and BioNTech. The accompanying manufacturing effort is just as onerous. Similarly, as …
The COVID-19 vaccine produced by Pfizer and BioNTech, Comirnaty, provides less protection against the omicron variant than it did against wild-type COVID and other variants, …
Like its partner on its COVID-19 vaccine, BioNTech keeps upping its estimate for 2021 vaccine revenue. Last week, Pfizer jacked up its annual guidance on …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
